
|Videos|November 27, 2013
The Difference Between Blocking PD-1 and PD-L1 in Melanoma
Author(s)Harriet Kluger, MD
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the difference between blocking PD-1 and PD-L1 in melanoma.
Advertisement
Clinical Pearls
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the difference between blocking PD-1 and PD-L1 in melanoma.
- The complete biology of PD-L1 is not known yet, though there is a theory that blocking it will be less toxic than blocking PD-1
- The toxicity and activity is different in PD-1 and PD-L1
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to ICT01 Plus Venetoclax/Azacitidine in AML
2
Teclistamab Improves PFS, OS in First Relapse of Multiple Myeloma
3
Elraglusib Combo Yields Notable 24-Month Survival Benefit in Metastatic PDAC
4
Suvemcitug Plus Chemo Improves PFS and OS in Recurrent Ovarian Cancer
5
















































